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Abstract: 
Objectives: to evaluate the effect of oral ginkgo 
biloba extract (GB)) on asymmetrical intrauterine 
growth restriction (IUGR). 
Study Design: A randomized trial conducted at 
Assiut Women Health on 226 pregnant women 
with asymmetrical IUGR. The patients randomly 
received GB extract or placebo for 6 weeks. The 
main outcome measures were improvement in 
fetal weight and feto-maternal blood flow. The 
data were analyzed by Student’s t- test and chi-
squared tests.  
Result: There was a significant increase in the 
estimated fetal weight in the GB group (3047+ 
127 gm) when compared to the placebo group 
(2734+ 127 gm) (p=<0.001). Moreover; there 
were significant increases in feto-maternal blood 
flow in GB group compared to the placebo 
group.  
Conclusions: GB extract improves placental 
functions, Doppler indices and fetal weight in 
pregnancies complicated with IUGR fetuses. 
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Introduction 
The use of herbal medicinal products is 
increasing enormously in recent years.1 
Many women are using them for 
menstrual problems, menopausal 
symptoms, mood disturbances and to 
strengthen their bones.2 Most of these 
benefits are due to the flavonoids 
present in these products. These 
flavonoids have anticarcinogenic, 
antiviral, antioxidant and anti-
inflammatory activities, as well as being 
used in the treatment of osteoporosis, 
menopausal symptoms and 
cardiovascular diseases.3 
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Besides the benefits from the 
consumption of flavonoids, little is 
known about their safety and potentially 
harmful toxic effects, such as 
mutagenicity and genotoxicity which 
might occur if taken in large doses.4 
GB is a flavonoid medicinal plant that 
has its origin in China, Korea and Japan 
where the fruit and leaves have been 
used as food and medicine for a long 
time.5 The major flavonoids in the GB 
extract are kaempferol, quercetin and 
isorhamnetin whose metabolites were 
found in the blood and urine after oral 
administration.6  
GB has not been reported in the 
evidence-based medicine literature as 
being either safe or contraindicated in 
pregnancy or lactation. A higher 
incidence of postpartum hemorrhage 
was reported in the literature when 
associated with a 3 months ingestion of 
GB extract.7  
Due to its actions as an anti-
inflammatory and antioxidant, GB has 
been largely used in the treatment of 
Alzheimer's disease, pre-menstrual 
syndrome, cerebrovascular insufficiency 
and peripheral arterial occlusive 
disease.8 In folk medicine, GB is used 
as a vermifuge, to induce labor, for the 
treatment of bronchitis, chronic rhinitis, 
chilblains, arthritis and edema.9  
Intrauterine growth restriction (IUGR) 
refers to a fetus that has failed to 
achieve a specific biometric or 
estimated weight threshold by a specific 
gestational age. Asymmetric IUGR is 
characterized by the head and brain 
being normal in size, but the abdomen is 
smaller. IUGR fetuses are at greater risk 
of stillbirth, birth hypoxia and neonatal 
complications.10  
Although there are many causes of 
asymmetrical IUGR, the treatment 
consists of either termination of 
pregnancy or remaining in utero and 
improving blood flow to the uterus. 
When blood flow is improved, the 
oxygen and other nutrients will deliver 
well to the fetus.11  
Many lines of treatment are available 
now for treatment of the asymmetric 
type of IUGR like maternal rest and 
oxygenation, aspirin therapy, 
supplementation of zinc and fish oil. 
However; all mentioned lines of 
treatment lack evidence of effectiveness 
in literature.12 
Our hypothesis is that the use of GB 
extract may improve the uterine blood 
flow and subsequently improve the 
placental functions and fetal weight. So 
the aim of this study was to evaluate the 
effect of oral supplementation of GB 
extract on the fetal weight as well as on 
the feto-maternal blood flow in cases of 
asymmetrical IUGR. 
To our knowledge, no randomized 
clinical trials have been conducted or 
registered, to test the effect of GB on 
fetal weight and Doppler blood flow in 
asymmetrical IUGR fetuses. 
Materials and Methods 
The current study is a clinically 
registered double blinded, parallel, 
randomized controlled trial 
(NCT02425436) compassing the effect 
of GB extract on pregnant women with 
asymmetrical IUGR. The ethical review 
board of the Faculty of Medicine of the 
Assiut University approved the study. 
The participants were recruited from our 
Obstetrics Outpatients Clinics of the 
Women’s Health Hospital, Assiut 
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University, Egypt. It was carried out in 
the period between the first of May 2014 
and the first of December 2015. This 
trial was designed and reported 
according to the revised 
recommendations of ClinicalTrials.gov 
for improving the quality of reporting 
RCTs. 
Eligible participants 
All pregnant women (28-30 weeks), 
whose pregnancy was complicated with 
asymmetrical IUGR were invited to 
participate in our study. Asymmetrical 
IUGR diagnosed by 2D transabdominal 
ultrasound (US) when the abdominal 
circumference (AC) reduced out of 
proportion to other fetal biometric 
parameters (biparietal diameter and 
head circumference) and is below the 
10th percentile, so there was increased 
HC:AC ratio.11 We included in our study 
women aged 20-35 years with normal 
Doppler indices in uterine, umbilical and 
middle cerebral arteries at time of 
recruitment (the normal value of S/D 
ratio is from 2.5-3.5; RI is from 0.60-0.75 
and of PI is from 0.96 -1.270, 
respectively).12 Informed consent was 
obtained for participation after 
discussing the nature of the study 
including the possible side effects of the 
GB.  
The recruited women entered the 
screening phase of the study. This 
phase included history taking (including 
parity and gestational age). All medical 
and surgical risks factors for IUGR were 
reviewed with the patient.13 Clinical 
assessment of BMI, blood pressure and 
fundal level were also done. 
We excluded women, aged ≤20 and ≥ 
35 years, women with hypertension, 
diabetes mellitus, smokers, low amniotic 
fluid volume, premature pre-labor 
rupture of membranes (PPROM), 
antepartum hemorrhage and fetal 
congenital anomalies. We also excluded 
women with abnormal Doppler indices 
at the time of recruitment in the form of 
Doppler indices > 2 SDs, absent 
diastolic flow or reversed flow. 
Randomization 
Randomization was done by the 
secretary of the Statistics Unit at Assiut 
University Hospital using a computer-
generated random table. Allocation 
concealment was done using serially 
numbered closed opaque envelopes. 
Each envelope was labeled with a serial 
number and had a card noting the 
intervention type. Allocation remained 
unchanged after opening of the closed 
envelopes. 
Intervention 
The eligible women were allocated to 
either group I (GB group); which 
received GB extract (Tebonina Forte 40 
mg, Epico, Egypt) two tablets per day 
for 6 weeks, while group II (placebo 
group) received two tablets of placebo 
per day for the same duration. The 
placebo tables had the same size, color, 
weight and shape of as the GB tablets, 
which were manufactured at the Faculty 
of Pharmacology, Assiut University, 
Egypt. Many studies had tested GB 120 
to 240 mg daily in divided doses in non-
pregnant women,14 however; here we 
tested a minimal dose (80 mg) of GB 
during pregnancy. 
Study outcomes 
The primary outcome was the 
improvement of fetal weight after 6 
weeks of GB use. Secondary outcomes 
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included Doppler blood flow changes in 
uterine, umbilical arteries and middle 
cerebral artery from before to 6 weeks 
after GB use.   
Follow-up schedule 
The follow up schedule was arranged 
according to Royal College of Obstetrics 
and Gynecology (RCOG) 
recommendations.13 The participants 
were followed up every 2 weeks; at 
each visit we were asking them about 
adequacy of fetal movement, then they 
were subjected to a 2 D obstetric 
ultrasound for fetal growth and a 
Doppler blood flow study of the uterine, 
umbilical and middle cerebral artery. 
Doppler blood flow changes in the 
umbilical artery were measured at free 
loop. Measurements of the uterine 
artery blood flow velocity waveforms 
were carried out in both uterine arteries. 
With patients in the recumbent position 
with a slight left lateral tilt, a device that 
combines B-mode-imaging and bi-
directional pulsed colored Doppler 
technique with real time spectral 
analysis (Sonoline G60 S Ultrasound 
imaging system, Siemens, Germany), 
using a convex probe 3.5 MHz, was 
used. The high pass filter was set at 125 
Hz. The blood flow velocity waveform 
was studied in the main trunk of both 
right and left uterine arteries, 2-3 cm 
medial to the anterior superior iliac 
spine.  
For measurement of the middle cerebral 
artery (MCA) blood flow, the fetal head 
was in the transverse plane and the 
color Doppler ultrasound was overlying 
the anterior wing of the sphenoid bone 
near the base of the skull with an angle 
that approximates zero degrees was 
achieved by moving the transducer on 
the maternal abdomen. The average 
value of systolic/ diastolic ration (S/D), 
resistance index (RI) and pulsatility 
index (PI) were calculated when three 
similar consecutive waves were 
obtained.22  
Final status of the participant 
Finally, the patients were classified into 
completed follow up or lost follow up. 
Treatment failure was defined as the 
need for termination of pregnancy due 
to static fetal growth over 3weeks or 
ominous Doppler indices in the form of 
absent end-diastolic blood flow or 
reversed flow. 
Sample size 
Sample size was calculated with 
assuming that power 90% and two sided 
C.I. 95%, so the needed sample size will 
be 113 in each arm with a total patients 
number is 226 (Epi-info™, Centers for 
Disease Control and Prevention, USA). 
Statistical analysis 
The data were entered on Microsoft 
Access database and analyzed using 
the Stat view by Apple. Comparisons 
between the groups were performed 
using Student’s t-test to compare the 
mean values between groups in scale 
variables. However, chi-squared tests 
were used to compare the dichotomous 
and ordinal variables in the groups. For 
analysis, P-value < 0.05 was considered 
significant.  
Results 
Out of 300 patients with evidence of 
asymmetrical IUGR, 226 consented to 
participate. The main reasons for not 
consenting included that they were 
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either not willing to share in an RCT (60 
patients) or had no reason for declining 
to participate (14 patients).  
Consenting women were randomized 
into two groups: GB group or placebo 
group. At the end of the study, 3 
patients (2.65%) were not included in 
the analysis in the GB group and 7 
patients (6.19%) were not included in 
placebo group; all of them were lost for 
follow-up. Therefore, their data were 
excluded from the final analysis and we 
included the data of only 110 patients in 
GB group and 106 patients in placebo 
group (Figure 1).  
 
The demographic characteristics of the 
participants are shown in Table 1. All 
studied women were found to be 
comparable as regard to age, BMI, 
parity, number of abortions, number of 
living children, number of previous CS 
and gestational age at time of 
recruitment. 
As shown in Table 2, both groups were 
comparable in estimated feral weight at 
baseline (p=0.81); however, after 6 
weeks of treatment, there was a 
significant increase in the estimated 
fetal weight (gm) in the GB group when 
compared to the placebo group 
(p=<0.001) (Table 2). 
As regard Doppler indices (S/D, RI and 
PI) of the uterine, umbilical and middle 
cerebral arteries; there were significant 
increases in blood flow (decreases in 
Doppler indices) of mentioned vessels in 
GB group when compared with placebo 
group (Table 3). 
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Table 1: Baseline characteristics of the participants 
Table 2: The main study outcomes 
 
 
Item 
 
Group I GB (n=110) 
 
Group II Placebo (n=106) 
 
p value 
Mean ± SD Mean ± SD 
 
 
Baseline 
 
After six weeks  
Estimated fetal weight (gm) 
 
 
1758+ 190 
 
1709+ 170 
 
 
0.81 
 
<0.001* 
3047+ 127 
 
2734+ 127 
 
* Statistical significant difference (P < 0.05) 
 
Discussion 
To our knowledge, this is the first 
randomized clinical study addressing 
the effect of GB extract on IUGR 
fetuses. In this study; we found a great 
benefit of GB extract on feto-placental 
blood flow. We observed a prominent 
decrease in Doppler blood flow indices 
of the uterine, umbilical and middle 
cerebral arteries after 6 weeks of use 
which was reflected by significant 
increase in fetal weight paving the way 
to put our hand on direct action of GB 
on maternal and fetal blood vessels. 
The rationale behind using this herbal 
extract in cases of intrauterine growth 
restriction was its proven ability to act as 
a free oxygen radical scavenger as well 
as to improve peripheral vascular 
circulation. Both actions could 
hypothetically act in a synergistic 
fashion to combat IUGR associated 
hypoxic patho-physiology.15  
IUGR is one of the most common and 
complicated problems in modern 
 
 
Characteristics 
 
Group I GB (n=113) 
 
Group II Placebo (n= 113) 
 
p value 
Mean ± SD Mean ± SD 
Age (years) 28.60 ± 6.43 27.50 ± 4.80 0.397 
Body mass index (BMI) 23.80 ± 2.23 23.90 ± 1.98 0.874 
Parity 2.90 ± 2.20 2.94 ± 1.94 0.870 
Number of abortions 0.19 ± 0.52 0.33 ± 0.84 0.515 
Number of living children 2.76 ± 1.82 2.93 ± 1.78 0.591 
Number of previous CS 0.93 ± 1.51 0.45 ± 0.63 0.482 
Gestational age  31.6+ 1.3 31.1+ 1.11 0.426 
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obstetrics. The corner stone in the 
treatment of the asymmetrical IUGR 
fetus in utero is improvement in utero-
placental blood flow.16 Many 
approaches have emerged to achieve 
that goal such as maternal bed rest and 
maternal hydration which are thought to 
have a role in increased blood flow to 
the uterus. The baby aspirin therapy 
remains controversial but theoretically it 
serves to preserve or improve blood 
flow to the placenta.17 The fish oil which 
contains omega 3 may be beneficial and 
many studies proved its great effect on 
treatment and prevention of IUGR.18  
Table 3: Doppler blood flow changes in uterine, umbilical and middle cerebral 
arteries from before to 6 weeks after treatment 
 
 
 
 
 
 
 
Uterine     
artery 
S/D 
Mean ± SD 
 
 
p-value 
RI 
Mean ± SD 
 
 
p-value 
PI 
Mean ± SD 
 
 
p-value Group I 
GB 
(n=110) 
Group II 
Placebo 
(n=106) 
Group I 
GB 
(n=110) 
Group II 
Placebo 
(n=106) 
Group I 
GB 
(n=110) 
Group II 
Placebo 
(n=106) 
 
Baseline 2.37±1.04 2.33±1.08 
 
0.314 0.51±0.14 
 
0.53±0.15 
 
0.261 0.82±0.38 
 
0.85±0.36 0.110 
After six 
weeks  
1.65±0.13 
 
2.11±0.33 
 
<0.01* 0.38±0.05 
 
0.46±0.08 
 
<0.01
* 
0.56±0.06 0.70±0.08 
 
<0.01* 
Umbilical 
artery 
 
Baseline 2.75±0.78 2.76±0.76 
 
0.571 0.61±0.11 
 
0.64±0.12 
 
0.325 0.99±0.28 
 
1.02±0.25 
 
0.084 
After six 
weeks  
2.04±0.48 
 
2.51±0.54 
 
<0.001* 0.41±0.08 
 
0.52±0.09 
 
<0.001
* 
0.56±0.06 
 
0.76±0.08 
 
<0.001
* 
Middle 
cerebral 
artery 
 
Baseline 5.59±0.94 
 
5.62±0.96 
 
0.541 0.82±0.04 
 
0.85±0.07 
 
0.238 1.79±0.38 
 
1.82±0.39 
 
0.260 
After six 
weeks  
4.16±0.30 
 
5.10±0.43 
 
<0.001* 0.50±0.02 
 
0.69±0.07 
 
<0.001* 1.12±0.41 
 
1.64±0.44 
 
<0.001* 
 
S/D systolic / diastolic, RI resistant index, PI pulsatility index  
* Statistical significant difference (P < 0.05) 
 
Zadroźna et al. studied placentas from 
IUGR pregnancies and found 
statistically significant lower 
cytochrome-c-oxidase activity of the 
trophoblast of IUGR and preterm 
placentas, which positively correlated 
with both newborn’s birth weight and 
placental weight. Consequently; they 
proposed hypoxia as one of possible 
factors leading to a premature birth and 
IUGR.19 
The effect of gingko biloba on circulation 
was proved in several studies. GB can 
increase cerebral and peripheral blood 
circulation, reduce vascular 
permeability, improve venous tone, 
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inhibit phosphodiesterase type 4 
(PDE4), relax vascular smooth muscle 
via a nitric oxide pathway, and improve 
blood flow to the corpus cavernosum of 
the penis.20  
Other beneficial effects of GB include 
decreases of systolic and diastolic blood 
pressure, increases in fasting plasma 
insulin and C-peptide, decreases of 
cortisol secretion and decreases in the 
secretion of corticotropic releasing 
hormone.21 
Although women during the child 
bearing period may use GB for a variety 
of indications, there are few reports in 
literature addressing use of GB during 
pregnancy. This may be because of 
previous disappointing results reported 
with the use of GB during pregnancy. 
Petty and his colleges in 2001 found a 
trace of colchicine in the placental blood 
of pregnant women having taken GB 
and concluded that GB supplement 
should be avoided by women who are 
pregnant or are trying to conceive.22 
However; the GB which was used in 
their study was adulterated with 
colchicines because it well known that 
GB hasn't any colchicines. 
Kudolo and his colleges proved that GB 
has platelet aggregation inhibition effect 
on animal models.23 However; they used 
120 mg of GB for 3 months (a much 
higher dose and longer time than we 
used). So we think that this effect is 
dose and duration dependent. In 
addition; no study, up to our knowledge, 
was conducted on pregnant women and 
proved that GB may prolong bleeding 
during delivery. 
There is only one systematic review in 
literature conducted by Dugoua and his 
colleges in 2006 that addressed the 
safety and efficacy of GB during 
pregnancy and lactation. They 
concluded that GB should be used with 
caution during pregnancy, particularly 
around labor where its anti-platelet 
properties could prolong bleeding time.8 
Moreover; they based their conclusion 
on animal models and they did not 
mention any study conducted on 
humans that proved this conclusion. 
We showed significant improvement in 
Doppler indices values among GB 
users. We propose that the positive 
effect of the extract on the placental 
circulation may be due to the antioxidant 
effect of GB. Similarly, GB extract 
significantly increased end diastolic 
velocity in the ophthalmic artery of 
glaucoma patients.24  
We think that our study has many 
positive points to be mentioned. Firstly; 
this is the first registered randomized 
trial that studied the effect of GB on 
IUGR fetuses. Secondly; it was a double 
blinded study in which the investigators 
were blinded regarding the intervention 
type during the follow up visits. Thirdly; 
our observations are also consistent 
with the hypothesis that GB may have a 
vasodilator effect which opens the way 
to use it in some important obstetric 
diseases such as pre-eclampsia and 
renal diseases which have not been 
studied before. 
Our study had several potential 
limitations. We used GB extract for only 
6 weeks not more, however; the long 
effect of GB should be emphasized. 
Despite that we found a significant 
increase in fetal weight, this may need 
to be compared to birth weight which is 
more accurate. Finally; the anti-platelet 
effect of GB could not be criticized here 
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because we used GB for 6 weeks only 
and we haven't information about 
delivery events; this may be addressed 
in another study. 
Conclusion  
The GB extract could improve placental 
functions, Doppler indices and fetal 
weight in IUGR fetuses. This effect is 
mostly due to an oxygen free radical 
scavenger action combined with a 
peripheral vascular improvement effect 
of the herb.  
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